June 5, 2026

Megan Macnaughtan, PhD
John Carroll University

Dear Dr. Macnaughtan,

SUBJECT: **INSTITUTIONAL BIOSAFETY COMMITTEE DETERMINATION**

Sponsor:	John Carroll University
Project:	**JCU-001, dated 04-30-2026**
Title:	Invertebrates Research

The WCG-administered Institutional Biosafety Committee (IBC) for John Carroll University has reviewed this research and made the following determination:

Meeting Date:	**June 5, 2026**
Meeting Type:	**Continuing Review of Project and Site**
IBC Determination:	☒ **Approved** ☐ **Disapproved** ☐ **Conditionally Approved** ☐ **Tabled** Applicable Section of the NIH Guidelines: III-D (various subsections)
Biosafety Level:	**BSL-1 plus Standard Precautions**
IBC Oversight Period:	**As long as active research continues**
Approval Expiration Date:	**June 30, 2028**

Reminder: per NIH requirements, IBC meeting minutes must be publicly posted on an institutional website after allowable redactions have been made. If you have not already done so, **please provide WCG with the institutional website where IBC meeting minutes are posted** via email to IBCServices@wcgclinical.com. Your IBC registration will then be updated with this information to maintain compliance.

If you have changes to your research to submit, please complete an IBC Change in Research Form and submit the completed form to IBCServices@wcgclinical.com.

cc: Rebecca Drenovsky, PhD, John Carroll University
Carole Krus, MS, CIP, John Carroll University
Study File

ALL IBC-APPROVED INVESTIGATORS MUST COMPLY WITH THE FOLLOWING:

1. Report the following site-specific information to the IBC within 5 days:
    a. Violations of the *Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules* (NIH Guidelines).
    b. New information bearing on the NIH Guidelines.
    c. Significant research-related accidents and/or illnesses.
    d. Research-related spills, exposures, and/or laboratory-acquired infections.
    e. Loss of containment.
    f. Suspension or termination of the study by the sponsor, investigator, or institution.
    g. Unresolved complaints related to biosafety.

2. Training:
    a. Be adequately trained in good microbiological techniques and IBC-approved standard operating procedures.
    b. Instruct and train the research staff in:
        i. The practices and techniques required to ensure safety;
        ii. The procedures for dealing with accidents, spills, and/or exposures.
    c. Inform the research staff of the reasons and provisions for any precautionary medical practices advised or requested.

3. Safety:
    a. Supervise the safety performance of the research staff to ensure that the required safety practices and techniques are employed.
    b. Make available to all research staff descriptions of the potential biohazards and the precautions to be taken.
    c. Adhere to IBC-approved emergency plans for handling accidental spills and personnel contamination.
    d. Remain in communication with the IBC throughout the conduct of the project.

4. Accountability:
    a. Correct work errors and conditions that may result in the loss of containment of recombinant or synthetic nucleic acid molecules.
    b. Ensure the integrity of the physical and biological containment of recombinant or synthetic nucleic acid molecules.
    c. Comply with shipping requirements for recombinant or synthetic nucleic acid molecules.
    d. Notify WCG IBC Services and obtain IBC approval before making any changes to the protocol, facilities, practices, and key study staff associated with the research.

The NIH Guidelines require that the IBC conduct periodic reviews of approved research. You will receive Continuing Review Report Forms from WCG IBC Services. These reports must be returned in a timely manner, even if research at your site has not yet begun.